Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label MAVIRET (glecaprevir/pibrentasvir). Show all posts
Showing posts with label MAVIRET (glecaprevir/pibrentasvir). Show all posts
Thursday, February 21, 2019

MAVIRET - AbbVie reaches an agreement with the pan-Canadian For HCV Drug

›
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET™ Feb. 21, 2019, 1...
Saturday, February 9, 2019

Mavyret - Safety and efficacy in patients receiving opioid substitution therapy/HCV genotypes 1-6

›
Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print] Safety and efficacy of glecaprevir/pib...
Monday, November 12, 2018

The Medicines Patent Pool Signs Licence With AbbVie to Expand Access to Key Hepatitis C Treatment, glecaprevir/pibrentasvir

›
The Medicines Patent Pool Signs Licence With AbbVie to Expand Access to Key Hepatitis C Treatment, glecaprevir/pibrentasvir  SAN FRANCIS...
Monday, May 7, 2018

Where the latest HCV drug combos fit in

›
Where the latest HCV drug combos fit in Publish date: May 6, 2018 His copanelist Norah Terrault, MD , agreed that these two regimens are ...
Tuesday, April 3, 2018

MAVIRET (Glecaprevir/pibrentasvir) treats hepatitis C in HIV-coinfected individuals

›
Glecaprevir/pibrentasvir treats hepatitis C in HIV-coinfected individuals Last Updated: 2018-04-02 By Reuters Staff NEW YORK (Reuters He...
Tuesday, February 6, 2018

AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™

›
AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™ - an oral therapy for the treatment of...
Wednesday, September 27, 2017

Japan - AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) of Chronic Hepatitis C in All Major Genotypes (GT1-6)

›
AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in...
Wednesday, September 20, 2017

Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience

›
Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.  Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Trea...
Friday, August 18, 2017

Hepatitis C - Newly Approved Mavyret Has High Response Rates

›
The Lancet Download Full Text Article - PDF provided by Henry E. Chang‏   via Twitter: Glecaprevir plus pibrentasvir for chronic hepati...
Thursday, August 17, 2017

AbbVie's MAVIRET Approved by Health Canada

›
AbbVie's MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes MAVIRET is the first a...
Friday, July 28, 2017

New At Hepatitis C Online: Vosevi and Mavyret

›
Hepatitis C Online is a free educational, web-based service that functions as a comprehensive resource for diagnosing, monitoring and manag...
Friday, June 23, 2017

Hepatitis C: AbbVies MAVIRET (glecaprevir/pibrentasvir) and Gilead’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) Receives CHMP Positive Opinion

›
AbbVies  MAVIRET (glecaprevir/pibrentasvir) and Gilead’s Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) Receives CHMP Positive Opinion Tw...